3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

10-K/A - BioNexus Gene Lab Corp (0001737523) (Filer)

10-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

NT 10-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l

KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation. Through this partnership, BGLC plans to leverage ML Tech's cutting-edge digital asset trading infrastru

KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company's new Ethereum-focused treasury strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum (ETH) as a strategic treasury asset, and is in line with recent announcements of Ethereum being included in the US "Crypto Strategic Reserve". Concurrently, BGLC has released its Ethereum Strategy Whitepaper, detailing the rationale behind the Company's decision and the broader significance of Ethereu

KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are pleased to announce the signing of a strategic teaming agreement (the "Agreement") to jointly develop and operate biogas plants across Malaysia. This collaboration marks a significant step in both companies' efforts to contribute to Malaysia's growing renewable energy sector, particularly in the generation of biogas from plantation wastewater. Strategic Collaboration for Sustainable Growth Under thi

KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. ("MRNA Scientific"), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. ("Vitarray"), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market. Under this agreement, MRNA Scientific will leverage its advanced medical testing facilities located in Kuala Lumpur, Malaysia, to provide

KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC, the "Company"))), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company's expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd. The partnership between the Company and Shenzhen Rongguang Health Group represents a significant step forward in developing advanced he

KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (NASDAQ:BGLC, the "Company"))), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September 2024, marking a significant milestone for the Company as it seeks to expand its portfolio and enhance its market presence globally. The investment and the launch of this new product line will all

KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB. AISB, a pioneering healthcare technology company, has become the first issuer to receive investment under the Environmental & Social Impact (ESI) scheme, part of t

KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare solutions. AISB specializes in innovative healthcare technologies, particularly through its flagship platform, aiCMS, which integrates advanced predictive analytics and AI tools to enhance c